Loading stock data…
INmune Bio Inc (INMB)
$1.62+0.20 (+14.08%)
Market ClosedLast close Jun 29
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
INmune Bio Inc. in the Healthcare sector is trading at $1.62 with a market capitalization of $33M. Wall Street consensus targets $7.00 (4 analysts), implying a +332.1% move over the next 12 months. The stock is currently 50% below its 52-week high of $3.24, remaining 3.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +332.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0↓ | $50,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.81M↓ | -$5.47M↑ | -$7.43M↑ | -$8.06M↑ | -$9.90M |
| Net Income | -$5.41M↓ | -$5.26M↑ | -$6.47M↑ | -$24.46M↓ | -$9.74M |
Peer Comparison
JNJUNHPFE
Fundamentals
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic ma...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$33.36M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-211.99%
Volume
Today's trading volume
1.35M
Recent News
INmune Bio (INMB) Q4 2025 Earnings Transcript
David Moss: Thank you, Dan, and good afternoon, everyone. Thank you for joining us for INmune Bio's Fourth Quarter and Full Year 2025 Earnings Call. Mark will then provide an update on our CORDStrom platform with a focus on our RDEB program.
INmune Bio (INMB) Q1 2026 Earnings Transcript
Need a quote from a Motley Fool analyst? David Moss: Thank you, Daniel, and good afternoon, everyone. For our first quarter 2026 earnings call, today, I'll review key takeaways and provide an update on our platform programs.
INmune Bio, Inc. Q1 2026 Earnings Call Summary
Moby summary of INmune Bio, Inc.'s Q1 2026 earnings call
INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
INmune Bio, Inc. Q4 2025 Earnings Call Summary
Moby summary of INmune Bio, Inc.'s Q4 2025 earnings call